Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines

Blood

Volumn 85, Issue 12, 1995, Pages 3566-3576

  Westendorf, Jennifer J ^b   Lammert, John M ^b   Jelinek, Diane F ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA FRAGMENT; FAS ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FAS; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN DETECTION; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL MATURATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL;

EID: 0029047066     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v85.12.3566.bloodjournal85123566     Document Type: Article

References (50)

1. Kyle RA: Current concepts on monoclonal gammopathies. Aust N Z J Med 22:291, 1992
2. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Tang B, Tanage O, Tanaka H, Kuramato A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332:83, 1988
3. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008, 1989
4. Zhang XG, Klein B, Bataille R: Interleukin 6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74:11, 1989
5. Klein B, Zhang XG, Jourdan M, Portier M, Bataille R: Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. Curr Top Microbiol Immunol 166:23, 1990
6. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747, 1989
7. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301, 1989
8. Owen-Schaub LB, Meterissian S, Ford RJ: Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J Immunother 14:234, 1993
9. Falk MH, Trauth BC, Debatin KM, Klas C, Gregory CD, Rickinson AB, Calender A, Lenoir GM, Ellwart JW, Krammer PH, Bornkamm GW: Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 79:3300, 1992
10. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415, 1993
11. Moller P, Henne C, Leithauser F, Eichelmann A, Schmidt A, Bruderlein S, Dhein J, Krammer PH: Coregulation of the APO-1 antigen with intracellular adhesion molecule (CD54) in tonsillar B cells and coordinate expression in follicular center cells and in follicular center and mediastinal center B-cell lymphomas. Blood 81:2067, 1993
12. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N: Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 149:3753, 1992
13. Daniel PT, Krammer PH: Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 152:5624, 1994
14. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen fas can mediate apoptosis. Cell 66:233, 1991
15. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Ponsting H, Krammer PH: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: Sequence identity with the Fas antigen. J Biol Chem 267:10,709, 1992
16. Pinto A, Gattei V, Sologo D, Parravicini C, Del Vecchio L: New molecules burst at the leukocyte surface: A comprehensive review based on the 5th international workshop on leukocyte differentiation antigens, Boston, USA, 3-7 November, 1993. Leukemia 8:347, 1994
17. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV: A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845, 1993
18. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314, 1992
19. Nagata S: Mutations in the Fas antigen gene in 1pr mice. Semin Immunol 6:3, 1994
20. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 76:969, 1994
21. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169, 1993
22. Suda T, Nagata S: Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 179:873, 1994
23. Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA: Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: Clinical implications. Cancer Res 53:5320, 1993
24. Wandl U, Hoang T, Minden M, Messner HA: Segregation of precursors with high proliferative potential from their differentiated progeny in a myeloma cell line. J Cell Physiol 136:384, 1988
25. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA: Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCO-My 1 to 7 established from patients with advanced stage of the disease. Blood 78:1996, 1991
26. Burke KH, Drewinko B, Trujillo JM, Aheam MJ: Establishment of a human plasma cell line in vitro. Cancer Res 38:2508, 1978
27. Matsuoka Y, Moore GE, Yagi Y, Pressman D: Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 125:1246, 1967
28. Nilsson K, Bennich H, Johansson SGO, Ponten J: Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 7:477, 1970
29. Deng G, Podack ER: Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci USA 90:2189, 1993
30. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF: CD40 expression in malignant plasma cells: Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 152:117, 1994
31. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 81:3357, 1993
32. Billadeau D, Ahmann G, Greipp P, Van Ness B: The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178:1023, 1993
33. Greipp PR, Witzig TE, Gonchoroff NJ: Immunofluorescent plasma cell labeling index using a monoclonal antibody (BU-1). Am J Hematol 20:289, 1985
34. Schwartzman RA, Cidlowski JA: Apoptosis: The biochemistry and molecular biology of programmed cell death. Endocrine Rev 14:133, 1993
35. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F, Lynch DH: Fas transduces activation signals in normal human T lymphocytes. J Exp Med 178:2231, 1993
36. Ault KA: Applications in immunology and lymphocyte analysis, in Melamed MR, Lindmo T, Mendelsohn ML (ed): Flow Cytometry and Sorting (ed 2). New York, NY, Wiley-Liss, 1990, p 694
37. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S: Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54:1580, 1994
38. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A: Phenotypic difference of normal plasma cells from mature plasma cells. Blood 81:2658, 1993
39. Kawano MM, Huang N, Harada H, Harada Y, Sakai A, Tanaka H, Iwato K, Kuramoto A: Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 82:564, 1993
40. Jensen GS, Poppema S, Mant MJ, Pilarski LM: Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. Int Immunol 1:229, 1989
41. Jensen GS, Mant MJ, Belch AJ, Berenson JR, Ruether BA, Pilarski LM: Selective expression in CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78:711, 1991
42. Jensen GS, Mant MJ, Pilarski LM: Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient. Am J Hematol 41:199, 1992
43. Pilarski LM, Jensen GS: Monoclonal circulating B cells in multiple myeloma. Hematol Oncol Clin North Am 6:297, 1992
44. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539, 1994
45. Mapara MY, Bargou R, Zugck C, Dohner H, Ustaoglu F, Jonker RR, Krammer PH, Dorken B: APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl-2 oncogene expression. Eur J Immunol 23:701, 1993
46. Korsmeyer SJ: Bcl-2: A repressor of lymphocyte death. Immunol Today 13:285, 1992
47. Itoh N, Tsujimoto Y, Nagata S: Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 151:621, 1993
48. Cuende E, Ales-Martinez JE, Ding L, Gonzalez-Garcia M, Martinez-A C, Nunez G: Programmed cell death by bcl-2-dependent and independent mechanisms in B lymphoma cells. EMBO J 12:1555, 1993
49. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759, 1994
50. Matsuda M, Masutani H, Nakamura H, Miyajima S, Yamauchi A, Yonehara S, Uchida A, Irimajiri K, Horiuchi A, Yodoi J: Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J Immunol 147:3837, 1991